3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Colorectal Neoplasms
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Temozolomide
2
LY3023414
2
Etoposide
2
thymoglobulin
1
temsirolimus
1
talazoparib
1
olaparib
1
irinotecan sucrosofate
1
fludarabine phosphate
1
amino-acid, glucose, and electrolyte solution
1
Vincristine
1
Vemurafenib
1
Thiotepa
1
Tacrolimus
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Maintenance
×
1 year
×
Clear all
NCT03011528
2025-11-21
CombinaiR3
Institut Curie
Phase 2
Completed
45 enrolled